Twenty patients with CRPS type I ( n = 16 ) and II of the upper limb and abnormally low PPT were double-blind randomised into 2 groups of 10 patients each to receive a 2-day intravenous treatment of either 80 mg parecoxib per day ( group I ) or placebo ( NaCl 0.9 % , group II ) .